Bleeding Disorders
News
Romiplostim now approved for children with ITP
The thrombopoietin receptor agonist romiplostim (NPlate®) is now approved by the U.S.
Conference Coverage
Rapid test could solve Africa’s sickle cell screening problem
SAN DIEGO – The simple blood test costs about $2 and has an accuracy of 99%.
Conference Coverage
Factor IX expression stable at up to 8 years with gene therapy
SAN DIEGO – In severe hemophilia B, factor IX expression remains stable up to 8.6 years after scAAV2/8-LP1-hFIX–comediated gene therapy.
Conference Coverage
DOAC pause yields favorable outcomes for AF patients
SAN DIEGO – Results from the PAUSE study could set the standard for timing of perioperative DOAC interruption.
Conference Coverage
Lower-dose rituximab may be enough in acquired TTP
SAN DIEGO – A lower dose of rituximab appears effective, but it still carries side effects.
Conference Coverage
MEDALIST: Erythroid maturation agent reduced transfusion burden in MDS
SAN DIEGO – Luspatercept also showed promise in a phase 3 trial including adults with beta-thalassemia.
From the Journals
Heavy menstrual bleeding in teens often linked to bleeding disorders
Over one-third of adolescents presenting with heavy menstrual bleeding were diagnosed with a bleeding disorder after screening.
Conference Coverage
Your guide to ASH 2018: Abstracts to watch
News
EC approves product for hemophilia A
The European Commission (EC) has approved damoctocog alfa pegol (Jivi®), a recombinant human factor VIII therapy. Damoctocog alfa pegol (formerly...
News
Canada expands approval for antihemophilic factor
Health Canada has extended the approved indication for Adynovate, a recombinant pegylated factor VIII (FVIII) product, in patients with hemophilia...
From the Journals
Invasive strategy increased bleeding risk in frail older AMI patients
Registry analysis suggests frailty in an AMI patient calls for personalized decision making.